Provectus says PV-10 effective in treating melanoma cells resistant to chemotherapy, radiation

By Lisa Kerner

Charlotte, N.C., Aug. 17 - Provectus Pharmaceuticals, Inc. said the active component of PV-10 (Provecta) is effective against melanoma cell lines that are resistant to chemotherapy and radiation, while leaving normal cells unharmed.

The company will present an abstract of its phase 1 clinical trial of PV-10 for ablation of metastatic melanoma, an aggressive form of skin cancer, at The Third Annual International Melanoma Research Congress in September.

In the study, each of 20 subjects having one or more tumors is being treated with a single injection of PV-10 and then observed for 12 to 24 weeks.

The trial is being conducted at two of the world's leading melanoma treatment and research centers in Australia, a country where the incidence of melanoma is more than twice that of the United States.

Provectus is a Knoxville, Tenn., biopharmaceutical company specializing in pharmaceutical technologies for the treatment of breast cancer, liver cancer and metastatic melanoma.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.